How AhR Agonism Is Changing Topical Treatment in Atopic Dermatitis

In this on-demand webinar, Mona Shahriari, MD, and G. Michael Lewitt, MD, explore AhR agonism as a distinct therapeutic class and consider what its multimodal mechanism may mean in practice.

They examine the evidence for tapinarof in moderate-to-severe AD, and the possibility of consecutive time off treatment after complete clearance. Throughout, they bring the data back to the questions that matter most in practice: where this option may fit, how to counsel patients and families, approaching sensitive sites and residual disease, and treatment goals that extend beyond improvement alone.